Derma Sciences, Inc. (DSCI) Announces Issuance of Two New U.S. Patents for DSC127
7/23/2012 10:12:08 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the issuance of patents 8,207,233 and 8,207,234 by the U.S. Patent and Trademark Office. These patents provide additional intellectual property protection for the Company’s investigational drug DSC127 by describing the angiotensin peptide in a specific formulation and a method of using the same to treat diabetic foot ulcers.